10.	Related Parties:

Dr. August J. Troendle, an officer and director of Medpace, which provides clinical development services to the Company, is a beneficial owner of more than 5% of the Company’s common shares. The Company incurred $568 and $941 of clinical development service fees under its priority access agreement and a master services agreement with Medpace for the three and six months ended June 30, 2016 (three and six months ended June 30, 2015 – $55). Additionally, the Company has recorded $1,996 of prepaid expenses as of June 30, 2016 (December 31, 2015 – $2,314) for future clinical development services under such agreements with Medpace.